This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
07/01/15 - 12:01:31 PM ET (BATS BZX Real-time Price)
Div Yield: --
DVAX Day's Range
DVAX 52 Week Range
DVAX Business Summary
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases.View DVAX key stats
Dynavax Technologies Corp - DVAX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Dynavax Technologies Corp as a
Sell with a ratings score of D.
Report Snippet: We rate DYNAVAX TECHNOLOGIES CORP (DVAX) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.